Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma Hall

Showing results (181-190 of 226) with videos related to

Pageof 23
Sort By:
Lancet (London, England)|March 9, 2020
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trialAlison Birtle, Mark Johnson, John Chester, et al.
Nature Genetics|July 1, 2014
A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1Laura Fachal, Antonio Gómez-Caamaño, Gillian C Barnett, et al.
The Lancet. Oncology|June 15, 2025
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trialAlison C Tree, Victoria Hinder, Andrew Chan, et al.
The New England Journal of Medicine|October 16, 2024
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate CancerNicholas van As, Clare Griffin, Alison Tree, et al.
European Urology|October 8, 2024
Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled TrialRobert Huddart, Shaista Hafeez, Clare Griffin, et al.
Lancet (London, England)|March 24, 2026
Proton beam therapy for oropharyngeal cancer (TORPEdO): a phase 3, randomised controlled trialDavid J Thomson, James M Price, Matthew Tyler, et al.
The Lancet. Oncology|March 13, 2022
Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trialDavid Dearnaley, Victoria Hinder, Adham Hijab, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2022
A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian CancerSusana Banerjee, Vasiliki Michalarea, Joo Ern Ang, et al.
The Lancet. Oncology|September 22, 2019
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trialDouglas H Brand, Alison C Tree, Peter Ostler, et al.
The New England Journal of Medicine|March 12, 2004
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancerR Charles Coombes, Emma Hall, Lorna J Gibson, et al.
Pageof 23

Showing results (181-190 of 226) with videos related to

Sort By:
Pageof 23
Lancet (London, England)|March 9, 2020
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trialAlison Birtle, Mark Johnson, John Chester, et al.
Nature Genetics|July 1, 2014
A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1Laura Fachal, Antonio Gómez-Caamaño, Gillian C Barnett, et al.
The Lancet. Oncology|June 15, 2025
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trialAlison C Tree, Victoria Hinder, Andrew Chan, et al.
The New England Journal of Medicine|October 16, 2024
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate CancerNicholas van As, Clare Griffin, Alison Tree, et al.
European Urology|October 8, 2024
Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled TrialRobert Huddart, Shaista Hafeez, Clare Griffin, et al.
Lancet (London, England)|March 24, 2026
Proton beam therapy for oropharyngeal cancer (TORPEdO): a phase 3, randomised controlled trialDavid J Thomson, James M Price, Matthew Tyler, et al.
The Lancet. Oncology|March 13, 2022
Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trialDavid Dearnaley, Victoria Hinder, Adham Hijab, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2022
A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian CancerSusana Banerjee, Vasiliki Michalarea, Joo Ern Ang, et al.
The Lancet. Oncology|September 22, 2019
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trialDouglas H Brand, Alison C Tree, Peter Ostler, et al.
The New England Journal of Medicine|March 12, 2004
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancerR Charles Coombes, Emma Hall, Lorna J Gibson, et al.
Pageof 23